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The number of pediatric heart transplants worldwide has 
continued to increase over time and is now around 600–700 
transplants per year (1). Despite this apparent increase, the 
number of centers performing pediatric heart transplants 
has remained stable since the late 1990s, with the majority 
of centers reporting an average of 1–4 transplants per 
year; while the remaining centers perform 5–9 or over ten 
transplants per year. Current survival is improving, with 
around 90% of patients achieving the 1-year mark, however 
current treatment practices are not standardized (2).
A recent analysis  of the organ procurement ad 
transplantation network (OPTN) revealed that there are 
significant differences in post-transplant patient and graft 
survival among currently active pediatric heart transplant 
centers in the United States (3). It was suggested that 
annual transplant volumes could somewhat explain these 
differences and short term performances, however, the 
analysis was limited to the information provided by the 
registry, which poorly defines center practices. There is 
limited knowledge about the uniformity of clinical practices 
in the pediatric heart transplant population to explain 
outcome variability.
Variability in clinical practices among institutions has 
been associated with inconsistent outcomes across multiple 
disease processes, with improvement seen when adherent to 
standardized clinical practices (4-7). Evaluation of protocols 
has become an important topic in all facets of medicine, 
including pediatric heart transplant (7-11). Several studies 
have attempted to identify variations in practices and 
analyze their differences to reach a consensus on best 
practices within pediatric heart transplant (9). In pediatric 
heart transplantation, clinical protocols tend to be center-
specific or experienced-based and extrapolated from less 
than ideal sources (10-12). Evidence-based guidelines based 
on clinical trials are mainly lacking.
Center variability also impedes the ability to perform 
quality clinical outcomes research using registries as a 
portion of the practice variations that could influence 
outcomes are not always collected. An example of this is 
the type and duration of CMV prophylaxis which has been 
shown to influence coronary allograft vasculopathy (CAV) 
outcomes (13-15). Other prophylaxis CAV medication use, 
maintenance immunosuppression targets, and treatment of 
donor specific antibodies are all other potential protocols 
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that can influence clinical outcomes and are largely missing 
in registry analysis.
Endomyocardial biopsy (EMB) remains the mainstay for 
the diagnosis of rejection; however, there is considerable 
variability in the frequency of monitoring amongst 
transplant programs, particularly within the first year post-
heart transplant (16). While there has been a decrease 
in the incidence of rejection in the more recent era of 
immunosuppression, there has been no significant change 
in the frequency of surveillance EMB over time (11). 
This may be due to the lack of information regarding the 
impact of changes in practices on outcomes, particularly 
in pediatrics. Though various non-invasive tests have been 
developed for evaluating for rejection, including advanced 
echocardiography, intramyocardial electrography, and 
gene expressions, these techniques are more frequently 
being used in the adult population and have yet to be 
validated in the pediatric population. This may suggest that 
better-designed studies correlating standardized rejection 
surveillance practices with clinical outcomes are needed and 
standardization could decrease exposure of the population 
to invasive procedures.
Steroids once were the mainstay of immunosuppressive 
therapies for solid organ transplantation, however, have 
significant side effects including Cushingoid facies, 
cataracts, obesity, hyperlipidemia, osteopenia, avascular 
bone necrosis, and severe growth retardation (12). Over 
time, programs have adapted steroid tapers or alternative 
steroid therapies, which have minimized the impact of 
secondary effects. However, hypertension, obesity, diabetes, 
and growth retardation remain common side effects. In 
a recent survey, most centers used a corticosteroid taper 
postoperatively, with the most common taper of 2–6 months 
and a small percentage of centers using a steroid-free 
protocol (1/28, 4%) (9). Database analyses and studies are 
still investigating the practicality of a steroid-free protocol.
Despite the challenges of reliable data for decision 
making, there is a high amount of uniformity in most 
areas of clinical practice (9). Previous surveys indicated 
consistency among programs with regards to infection 
prophylaxis with most centers reporting similar protocols 
for fungal, CMV, and pneumocystis carinii (>80%). There 
was also strong agreement with regards to maintenance 
immunosuppression with most centers (>85%) prescribing 
tacrolimus and mycophenolate mofetil at the time of 
discharge (9).
Fortunately, there appears to be a willingness to change 
clinical practices as part of an effort to form a single 
protocol (9). Recently, a randomized control trial was 
initiated using a uniform post-transplant protocol and 
includes over 35 pediatric heart transplant centers (17). This 
trial (TEAM-MATE) also standardizes two maintenance 
immunosuppression regimes, including the therapeutically 
monitored tacrolimus and everolimus. There is additional 
interest within the pediatric heart transplant community to 
expand on this effort with other aspects of post-transplant 
care through loose collaboration between centers with 
similar protocols. Though it is unlikely that all practices 
can be standardized through randomized control trials 
given the size of the population and cost of funding, 
center cooperation is a potential tool to broadening the 
understanding of the impact of different clinical pathways 
on outcomes.
While there exist such variations among pediatric heart 
transplant centers, the majority of the major components of 
clinical practice protocols are similar. To adequately power 
an RCT in pediatric heart transplantation, study design 
must minimize potential confounding due to variation 
in clinical practice patterns. There have been several 
initiatives to standardize practices by the Pediatric Heart 
Transplant Society, however, expecting all centers to agree 
on one protocol may not be feasible. While we have made 
significant gains in pediatric heart transplant outcomes, a 
movement towards a standard protocol to refine clinical 
outcomes research is vital to further improvement of long 
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